Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions (2022 - 2026)

Gyre Therapeutics has reported Tax Provisions over the past 7 years, most recently at $2.4 million for Q4 2025.

  • Quarterly Tax Provisions rose 99.83% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, down 10.41% year-over-year, with the annual reading at $5.7 million for FY2025, 10.41% down from the prior year.
  • Tax Provisions was $2.4 million for Q4 2025 at Gyre Therapeutics, up from $1.7 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $5.1 million in Q4 2022 and troughed at $662000.0 in Q2 2025.
  • The 4-year median for Tax Provisions is $1.7 million (2025), against an average of $2.0 million.
  • Year-over-year, Tax Provisions plummeted 86.29% in 2023 and then soared 99.83% in 2025.
  • A 4-year view of Tax Provisions shows it stood at $5.1 million in 2022, then plummeted by 86.29% to $699000.0 in 2023, then surged by 72.39% to $1.2 million in 2024, then soared by 99.83% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Tax Provisions are $2.4 million (Q4 2025), $1.7 million (Q3 2025), and $662000.0 (Q2 2025).